{"id":"nct:NCT02493868","kind":"trial","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","authors":["Janssen Research & Development, LLC"],"author_count":1,"year":2015,"published":"2015-07-10","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT02493868","source_url":"https://clinicaltrials.gov/study/NCT02493868","archive_url":"https://space-kitty.com/papers/nct:NCT02493868","updated":"2025-04-29","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms in participants with treatment-resistant depression (TRD) who are in stable remission after an induction and optimization course of intranasal esketamine plus an oral antidepressant.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Depressive Disorder, Treatment-Resistant"],"details":{"acronym":"SUSTAIN-1","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":719,"sponsor":"Janssen Research & Development, LLC","conditions":["Depressive Disorder, Treatment-Resistant"],"interventions":["DRUG: Esketamine","DRUG: Placebo","DRUG: Duloxetine (Oral Antidepressant)","DRUG: Escitalopram (Oral antidepressant)","DRUG: Sertraline (Oral Antidepressant)","DRUG: Venlafaxine Extended Release (XR) (Oral Antidepressant)"],"start_date":"2015-10-01","start_date_type":"ACTUAL","primary_completion_date":"2018-02-15","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[{"slug":"psychiatric-therapeutics","title":"Novel Psychiatric Therapeutics: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/psychiatric-therapeutics"}]}